Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Endocrine 1CNS 1

Conditions

Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Multiple Endocrine Neoplasia Type 2a 1Medulloblastoma 1Lethal Congenital Contracture Syndrome 2 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1273Specimen Handling 871Carboplatin 832Magnetic Resonance Spectroscopy 808Cyclophosphamide 803Cisplatin 729Nivolumab 659Paclitaxel 631Radiotherapy 574Gemcitabine 572Biopsy 529Bevacizumab 476Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 358Fluorouracil 355atezolizumab 344durvalumab 334Rituximab 333Doxorubicin 317Radiosurgery 309Pemetrexed 306Drug Therapy 303Ipilimumab 294Standard of Care 293Etoposide 285Radiation 281

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Vascular Endothelial Growth Factor A × 1 year × Clear all
NCT07346157 2026-06-01

PNOC044

University of California, San Francisco

Phase 1/2 Not yet recruiting
69 enrolled
CNS

Medulloblastoma

NCT01871766 2026-04-24

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
115 enrolled
Sarcoma

Rhabdomyosarcoma

NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡